<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20040924102011+02'00'</creation_date><modification_date>D:20040924102011+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-04-290_h_dec_0.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 20.09.2004 c(2004) 3580 
 not for publication</p></section><section><header>commission decision of 20.09.2004 
 granting the marketing authorization for the medicinal 
  
 product for human use, 
  
 &quot;alimta - pemetrexed&quot; 
 (text with eea relevance)</header><p>only the dutch text is authentic</p></section><section><header>en  
   en</header></section><section><header>commission decision of 20.09.2004 
 granting marketing authorisation for the medicinal product for human use &quot;alimta 
 - pemetrexed&quot; under council regulation (eec) no 2309/93 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, as amended by commission regulation (ec) no 649/982, and in particular article 10(2) thereof, 
 having regard to the application submitted by eli lilly nederland b.v., on 18 august 
 2003, under article 4(1) of regulation (eec) no 2309/93, 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 23 june 2004, 
 whereas: 
 (1)</p><p>the medicinal product &quot;alimta - pemetrexed&quot; complies with the requirements set 
 out in directive 2001/83/ec of the european parliament and of the council of 6 
 november 2001 on the community code relating to medicinal products for 
 human use
 3 as amended by directive 2002/98/ec4 and by directive 2003/63/ec5. (2)</p><p>it is therefore appropriate to authorise its placing on the market. 
 (3)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 1 oj l 214, 24. 8. 1993, p. 1. 2 oj l 88, 24.3.1998, p. 7. 3 oj l 311, 28.11.2001, p. 67. 4 oj l 33, 8.2.2003, p. 30. 5 oj l 159, 27.6.2003, p. 46.</p></section><section><header>en  
   en</header><p>has adopted this decision: article 1 the marketing authorization referred to in article 3 of regulation (eec) no 2309/93 is hereby granted in respect of the medicinal product, &quot;alimta - pemetrexed&quot; whose 
 characteristics are summarized in annex i hereto. this medicinal product shall be entered 
 in the community register of medicinal products under the numbers: 
 eu/1/04/290/001 
 alimta-500 mg-powder for concentrate for solution for infusion-
 intravenous use-vial (glass)-1 vial 
 article 2 the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to 
 manufacture and importation, control and issue referred to in annex ii. 
 article 3 the labelling and package leaflet concerning the medicinal product referred to in article 1 shall conform to annex iii. 
 article 4 the period of validity of the authorization issued shall be five years from the date of notification of this decision. 
 article 5 this decision is addressed to eli lilly nederland b.v., grootslag 1-5, 3991 ra houten, nederland. 
 done at brussels, 20.09.2004 
 for the commission olli rehn 
 member of the commission</p></section></body></xml>